Stocks Health care MOLN
NASDAQ · Health careMolecular Partners AG (MOLN)
Molecular Partners AG reported revenue of CHF 0 in fiscal 2025, down 100.0% from a year earlier. It posted a net loss of CHF 61.7M. In fiscal 2025 capital spending exceeded operating cash flow by CHF 52M. At December 31, 2025 it held CHF 82.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 12, 2026.
What Molecular Partners AG does
Molecular Partners AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MOLN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | CHF 0 | -CHF 61.7M | -CHF 1.65 | -CHF 52M |
| 2024 | CHF 5M | -CHF 54M | -CHF 1.59 | -CHF 60M |
| 2023 | CHF 7M | -CHF 62M | -CHF 1.89 | -CHF 59.6M |
| 2022 | CHF 189.6M | CHF 117.9M | CHF 3.54 | CHF 117.4M |
| 2021 | CHF 9.8M | -CHF 63.8M | -CHF 2.06 | -CHF 91.9M |
| 2021 | CHF 9.3M | -CHF 62.8M | -CHF 2.51 | -CHF 30.4M |
Latest SEC filings
What Molecular Partners AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 25, 2026
- July 20, 2026
- July 7, 2026
- July 2, 2026
- June 24, 2026
- June 1, 2026
- May 12, 2026
- May 1, 2026
- April 14, 2026
- March 30, 2026
Questions about MOLN
What does Molecular Partners AG do?
Molecular Partners AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MOLN.
Is Molecular Partners AG profitable?
No. In fiscal 2025 it reported a net loss of CHF 61.7M.
How much revenue does Molecular Partners AG make?
In fiscal 2025 Molecular Partners AG reported revenue of CHF 0. That is 100.0% less than a year earlier.
When did Molecular Partners AG last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 12, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 25, 2026.
Similar companies
Follow MOLN
Get an email when Molecular Partners AG files with the SEC: results, executive changes, material agreements and annual reports.
Follow MOLN: get an email when it filesWhere the numbers come from
Financial figures are the values Molecular Partners AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.